| Table 1: Patient characteristics (age, sex, anatomical site in colon, lymph node stage, Lynch syndrome) stratified by distant metastasis. | | | |
| --- | --- | --- | --- |
|  | **Total (N=57)** | **No Distant Metastatic Disease (N=38)** | **Distant Metastatic Disease (N=19)** |
| All patients were diagnosed with stage III colorectal cancer. | | | |
| **Sex** |  |  |  |
| Male | 33 (57.9%) | 21 (55.3%) | 12 (63.2%) |
| Female | 24 (42.1%) | 17 (44.7%) | 7 (36.8%) |
| **Age (years)** |  |  |  |
| <40 | 2 (3.5%) | 1 (2.6%) | 1 (5.3%) |
| 40-49 | 7 (12.3%) | 4 (10.5%) | 3 (15.8%) |
| 50-59 | 6 (10.5%) | 3 (7.9%) | 3 (15.8%) |
| 60-69 | 16 (28.1%) | 10 (26.3%) | 6 (31.6%) |
| 70-79 | 12 (21.1%) | 12 (31.6%) | 0 (0%) |
| 80+ | 14 (24.6%) | 8 (21.1%) | 6 (31.6%) |
| **Anatomical Site in Colon** |  |  |  |
| Cecum | 17 (29.8%) | 14 (36.8%) | 3 (15.8%) |
| Hepatic Flexure | 2 (3.5%) | 2 (5.3%) | 0 (0%) |
| Left Colon | 6 (10.5%) | 4 (10.5%) | 2 (10.5%) |
| Rectum | 12 (21.1%) | 4 (10.5%) | 8 (42.1%) |
| Right Colon | 6 (10.5%) | 4 (10.5%) | 2 (10.5%) |
| Sigmoid | 7 (12.3%) | 6 (15.8%) | 1 (5.3%) |
| Splenic flexure | 1 (1.8%) | 1 (2.6%) | 0 (0%) |
| Splenic Flexure | 1 (1.8%) | 0 (0%) | 1 (5.3%) |
| Transverse colon | 3 (5.3%) | 2 (5.3%) | 1 (5.3%) |
| Transverse Colon | 1 (1.8%) | 1 (2.6%) | 0 (0%) |
| Missing | 1 (1.8%) | 0 (0%) | 1 (5.3%) |
| **Lymph Node Involvement Stage** |  |  |  |
| Stage 0 | 29 (50.9%) | 25 (65.8%) | 4 (21.1%) |
| Stage 1A | 11 (19.3%) | 7 (18.4%) | 4 (21.1%) |
| Stage 1B | 7 (12.3%) | 1 (2.6%) | 6 (31.6%) |
| Stage 1C | 2 (3.5%) | 2 (5.3%) | 0 (0%) |
| Stage 2 | 1 (1.8%) | 1 (2.6%) | 0 (0%) |
| Stage 2A | 5 (8.8%) | 2 (5.3%) | 3 (15.8%) |
| Stage 2B | 2 (3.5%) | 0 (0%) | 2 (10.5%) |
| **MLH1 (Lynch syndrome)** |  |  |  |
| Loss of Function | 16 (28.1%) | 11 (28.9%) | 5 (26.3%) |
| Gain of function | 41 (71.9%) | 27 (71.1%) | 14 (73.7%) |
| **MSH2 (Lynch syndrome)** |  |  |  |
| Gain of function | 57 (100%) | 38 (100%) | 19 (100%) |